Neuren Pharmaceuticals’ partner Acadia Pharmaceuticals secured European Commission approval for DAYBU (trofinetide) to treat Rett syndrome symptoms in patients aged five and older, marking the first EU-authorised treatment for this condition.
- DAYBU gains first EU marketing authorisation for Rett syndrome
- Approval covers all 27 EU states plus Iceland, Liechtenstein, Norway
- Neuren to receive US$35 million on first sale plus up to US$170 million milestones
- Commercial launch in Germany expected early Q4 2026
- Trofinetide not yet approved in Australia
DAYBU Becomes First Rett Syndrome Treatment Approved in Europe
Neuren Pharmaceuticals (ASX:NEU) has hit a major regulatory milestone as its exclusive licensee, Acadia Pharmaceuticals (Nasdaq: ACAD), announced the European Commission’s marketing authorisation for DAYBU (trofinetide). This approval designates DAYBU as the first and only treatment authorised in the European Union for neurobehavioral symptoms of Rett syndrome in patients aged five years and older.
The significance for families and clinicians managing this rare neurological disorder is considerable, as no approved therapies have existed in Europe until now. The approval extends across all 27 EU member states, as well as Iceland, Liechtenstein, and Norway, positioning DAYBU for broad market access.
Commercial Launch and Financial Upside for Neuren
Acadia plans to launch DAYBU commercially in Germany early in Q4 2026, a key European market. Under the licensing deal, Neuren is entitled to a US$35 million payment upon first commercial sale in Europe. Beyond this, escalating annual net sales could trigger up to US$170 million in milestone payments, alongside tiered royalties ranging from mid-teens to low-20s percentages of net sales.
This regulatory green light follows a string of approvals for DAYBU in other territories, including the US, Canada, and Israel. While trofinetide remains unapproved in Australia, this European endorsement adds a critical revenue stream and validates Neuren’s long-term strategy targeting neurological disorders with high unmet medical need.
Pipeline Progress and Ongoing Clinical Trials
Neuren’s pipeline extends beyond DAYBU, with NNZ-2591 (ercanetide) advancing through Phase 3 trials for neurodevelopmental disorders such as Phelan-McDermid syndrome. The ongoing “Koala” trial is evaluating safety and efficacy in children aged 3 to 12 years, supported by orphan drug designations and expedited regulatory pathways in the US and EU.
Neuren’s CEO Jon Pilcher emphasised the company’s commitment to addressing serious neurological conditions lacking effective treatments. The European approval of DAYBU not only opens new markets but also reinforces confidence in Neuren’s approach to developing peptide analog therapies targeting brain IGF-1 pathways.
Bottom Line?
Neuren’s European approval for DAYBU unlocks substantial milestone payments and sets the stage for commercial expansion in a key global market.
Questions in the middle?
- How rapidly will DAYBU uptake progress across diverse European markets beyond Germany?
- What impact will the European launch have on Neuren’s overall royalty revenue trajectory in 2027 and beyond?
- How will Neuren balance advancing NNZ-2591 trials alongside maximising DAYBU’s commercial potential?